Michele De Bortoli is at present Full Professor of Molecular Biology at the Faculty of Sciences of the University of Turin.

Transcript

1 CURRICULUM VITAE Prof. Michele De Bortoli Michele De Bortoli is at present Full Professor of Molecular Biology at the Faculty of Sciences of the University of Turin. He is Director of the Interdisciplinary Research Cluster "Molecular Systems Biology" of the University of Turin. He is member of the Faculty of the PhD Programme "Complex Systems for Life Sciences of the PhD School Life and Health Sciences". Michele De Bortoli is a member of the Dept. of Oncological Sciences at the Institute for Cancer Research and Treatment in Candiolo (Turin) and leads an interdisciplinary research group working at the LIMA Laboratories, Bioindustry Park Silvano Fumero (Colleretto Giacosa, Turin) and at the Molecular Systems Biology at the University of Turin. Education and experience. Born in Susa (Turin) the 7th of June, 1954, he graduates "cum laude" in Biology in 1978 at the University of Turin, with a Thesis in Enzymology Post doctoral fellow at the RBM "A.Marxer" Institute for Biomedical Research in Ivrea (Turin), working on tissue tumor markers Visting Associate at the Laboratory of Pathophysiology and Laboratory of Tumor Biology and Immunology, National Cancer Institute, Bethesda (US), where he investigates the role of protooncogenes in mammary tumors Assistant Professor in Biochemistry at the Dept. of Animal Biology in Turin, where he studies the role of proto oncogenes in mammary development and cancer Visiting Scientist at the Friedrich Miescher Institute of Basel (Switzerland), studying the crosstalk between estrogen and growth factor receptors in the control of cell growth Assistant Professor and Group Leader at the Dept. of Animal & Human Biology in Turin, leads a group working on the transcriptional control by estrogen and growth factors Visiting Scientist at the University of California at San Diego, Cell & Molecular Biology, to setup the chromatin immunoprecipitation assay.

2 Scientific supervisor of the Laboratory of Gynecological Oncology at Institute for Cancer Research & Treatment, Candiolo. Research programmes focus on: i) the role of estrogen in global gene expression regulation, with dissection of cofactors and secondary mediators of genomic responses to estrogen; ii) the role of AP 2 transcription factors in neoplastic growth control; iii) gene expression profiling in tumors for prognosis and endocrine therapy response prediction Founder and Director of the Centro Interdipartimentale Sistemi Complessi in Biologia e Medicina Molecolare of the University of Turin, now changed to Molecular Systems Biology research cluster today Michele De Bortoli establishes a research group at the LIMA Laboratories, Bioindustry Park (Colleretto Giacosa, Torino), running R&D activity on the developments of pharmacological targets to revert endocrine therapy resistance in breast cancer. At the same time, he leads a collaborative group within the Molecular Systems Biology studying various aspects of gene regulation, including novel activities of estrogen receptor alpha end coregulatory proteins, mirna expression and regulation in breast cancer cells and genomic mapping of estrogen receptor alpha and components of this pathway. He has been and is today responsible of several research grants from public and private funding agencies (EORTC, CNR, MURST, FIRB, Ministry of Health, Regione Piemonte, AIRC, ABO, Zeneca, ARES Serono). He is member of the editorial board of the International Journal of Biological Markers, active member of the American Association for Cancer Research and member of the Italian Society of Biophysics and Molecular Biology. He is also member of the Scientific Secretary of the ABO Association (Biotechnology Applications in Oncology), Venice. He authored more than 90 scientific publications, either in international journals, or as scientific book chapters and articles for scientific information. Teaching duties and administration/organization related activities. Since 1991, Michele De Bortoli is responsible of the Molecular Biology classes for Biology undergraduates (first and second level) and, since 2000, of the classes of Recombinant Technology, Applied Molecular Biology & Genetics. More recently, he also teaches to Biotechnology undergraduates Laboratory techniques in Molecular Biology and Biomaterials for Chemistry undergraduates.

3 From 2001 to 2007 he was Coordinator of the second level degree (Laurea Magistrale) in Biomolecular Sciences, University of Turin. Since 2005, he is responsible of projects for Student laboratories of the Faculty of Sciences, focusing on the development of Bioinformatics and Computational Biology facilities. Since 2006, he founded and directed the SysBioM Cluster (Centro Interdipartimentale Sistemi Complessi in Biologia e Medicina Molcolare) of the University of Turin.

4 Scientific Publications Papers 1. Cutrupi S, Reineri S, Panetto A, Grosso E, Caizzi L, Ricci L, Friard O, Agati S, Scatolini M, Chiorino G, Lykkesfeldt AE, De Bortoli M. Targeting of the adaptor protein Tab2 as a novel approach to revert tamoxifen resistance in breast cancer cells. Oncogene Jan 16. doi: /onc [Epub ahead ofprint] Corrigendum in press. 2. Ferraro L, Ravo M, Nassa G, Tarallo R, De Filippo MR, Giurato G, Cirillo F, Stellato C, Silvestro S, Cantarella C, Rizzo F, Cimino D, Friard O, Biglia N, De Bortoli M, Cicatiello L, Nola E, Weisz A. Effects of Oestrogen on MicroRNA Expression in Hormone Responsive Breast Cancer Cells. Horm Cancer Jan 25. [Epub ahead of print] PubMed PMID: Courtin A, Communal L, Vilasco M, Cimino D, Mourra N, de Bortoli M, Taverna D, Faussat AM, Chaouat M, Forgez P, Gompel A. Glucocorticoid receptor activity discriminates between progesterone and medroxyprogesterone acetate effects in breast cells. Breast Cancer Res Treat. 2012; 131(1): Friard O, Re A, Taverna D, De Bortoli M, Corá D. CircuitsDB: a database of mixed microrna/ transcription factor feed forward regulatory circuits in human and mouse. BMC Bioinformatics Aug 23;11: Cicatiello L, Mutarelli M, Grober OM, Paris O, Ferraro L, Ravo M, Tarallo R, Luo S, Schroth GP, Seifert M, Zinser C, Chiusano ML, Traini A, De Bortoli M, Weisz A. Estrogen receptor alpha controls a gene network in luminal like breast cancer cells comprising multiple transcription factors and micrornas. Am J Pathol May;176(5): Fortunati N, Bertino S, Costantino L, De Bortoli M, Compagnone A, Bandino A, Catalano MG, Boccuzzi G. Valproic acid restores ER alpha and antiestrogen sensitivity to ER alpha negative breast cancer cells. Mol Cell Endocrinol Jan 15;314(1):17 22.

5 7. Orso F, Jager R, Calogero RA, Schorle H, Sismondi P, De Bortoli M, Taverna D. AP 2α Regulates Migration of GN 11 Neurons via a Specific Genetic Program involving the AXL receptor tyrosine kinase BMC Biol May 22;7: Cardamone MD, Bardella C, Gutierrez A, Di Croce L, Rosenfeld MG, Di Renzo MF, De Bortoli M. ERalpha as ligand independent activator of CDH 1 regulates determination and maintenance of epithelial morphology in breast cancer cells. Proc Natl Acad Sci U S A. 2009, 106(18): (Epub 2009 Apr 21). 9. Cimino D, Fuso L, Sfiligoi C, Biglia N, Ponzone R, Maggiorotto F, Russo G, Cicatiello L, Weisz A, Taverna D, Sismondi P, De Bortoli M Identification of new genes associated with breast cancer progression by gene expression analysis of pre defined sets of neoplastic tissues. Int J Cancer, 2008, 123: (DOI: 23660) 10. Orso F, Penna E, Cimino D, Astanina E, Maione F, Valdembri D, Giraudo E, Serini G, Sismondi P, De Bortoli M, Taverna D. AP 2 α and AP 2 γ Regulate Epithelial Tumor Progression via Specific Genetic Programs FASEB J, 2008, Pubblicato on line: doi: /fj Ravo M, Mutarelli M, Ferraro L, Grober OMV, Paris O, Tarallo R, Vigilante A, Cimino D, De Bortoli M., Nola E, Cicatiello L, Weisz A. Quantitative expression profiling of highly degraded RNA from formalin fixed, paraffinembedded breast tumor biopsies by oligonucleotide microarrays. Laboratory Investigation, 2008; 88: Sismondi P, Biglia N, Ponzone R, Fuso L, Scafoglio C, Cicatiello L, Ravo M, Weisz A, Cimino D, Altobelli G, Friard O, De Bortoli M. Influence of estrogens and antiestrogens on the expression of selected hormone responsive genes. Maturitas. 2007, 57(1):50 5. Epub 2007 Mar Orso F, Fassetta M, Penna E, Solero A, De Filippo K, Sismondi P, De Bortoli M, Taverna D. The AP 2alpha Transcription Factor Regulates Tumor Cell Migration and Apoptosis. Adv Exp Med Biol. 2007; 604:87 95

6 14. Filigheddu N, Cutrupi S, Porporato PE, Riboni F, Baldanzi G, Chianale F, Fortina E, Piantanida P, De Bortoli M, Vacca G, Graziani A, Surico N. Diacylglycerol Kinase is Required for HGF induced Invasiveness and Anchorageindependent Growth of MDA MB 231. Breast Cancer Cells. Anticancer Res. 2007, 27: Scafoglio C, Ambrosino C, Cicatiello L, Altucci L, Ardovino M, Bontempo P, Medici N, Molinari AM, Nebbioso A, Facchiano A, Calogero RA, Elkon R, Menini N, Ponzone R, Biglia N, Sismondi P, De Bortoli M, Weisz A. Comparative gene expression profiling reveals partially overlapping but distinct genomic actions of different antiestrogens in human breast cancer cells. J Cell Biochem. 2006, 98: De Bortoli M, Biglia N. Gene Expression Profiling with DNA Microarrays Revolutionary Tools to Help Diagnosis, Prognosis, Treatment Guidance, and Drug Discovery. In Biomarkers in breast cancer: molecular diagnostics for predicting and monitoring therapeutic effect Ed. by G. Gasparini & D. F. Hayes. Humana Press, Totowa, NJ 07512, US, 2005: Bardella C, Costa B, Maggiora P, Patane' S, Olivero M, Ranzani GN, De Bortoli M, Comoglio PM, Di Renzo MF. Truncated RON tyrosine kinase drives tumor cell progression and abrogates cell cell adhesion through E cadherin transcriptional repression. Cancer Res. 2004, 64: Cicatiello L, Scafoglio C, Altucci L, Cancemi M, Natoli G, Facchiano A, Iazzetti G, Calogero R, Biglia N, De Bortoli M, Sfiligoi C, Sismondi P, Bresciani F and Weisz A A Genomic View of Estrogen Actions in Human Breast Cancer Cells by Expression Profiling of the Hormone Responsive Transcriptome J Mol Endocrinol 2004, 32: Weisz A, Basile W, Scafoglio C, Natoli G, Altucci L, Bresciani F, Facchiano A, Sismondi P, Cicatiello L, De Bortoli M Molecular identification of ERa positive breast cancer cells by the expression profile of a set of hormone regulated genes. J Cell Physiol 2004; 200: Orso F, Cottone E, Hasleton MD, Ibbitt CJ, Sismondi P, Hurst HC, De Bortoli M. AP 2gamma expression is specifically induced by estrogens through binding of the estrogen receptor to a canonical element within the 5 untranslated region. Biochem J. 2004, 377:

7 21. Sorbello V, Fuso L, Sfiligoi C, Scafoglio C, Ponzone R, Biglia N, Weisz A, Sismondi P, De Bortoli M. Quantitative real time RT PCR analysis of eight novel estrogen regulated genes in breast cancer. Int J Biol Markers. 2003, 18: Biglia N, De Bortoli M. Molecular characterization of breast cancer aggressiveness. Int J Biol Markers. 2003, 18: Sfiligoi C, de Luca A, Cascone I, Sorbello V, Fuso L, Ponzone R, Biglia N, Audero E, Arisio R, Bussolino F, Sismondi P, De Bortoli M. Angiopoietin 2 expression in breast cancer correlates with lymph node invasion and short survival. Int J Cancer. 2003, 103(4): Modugno M, Tagliabue E, Ardini E, Berno V, Galmozzi E, De Bortoli M, Castronovo V, Menard S. p53 dependent downregulation of metastasis associated laminin receptor. Oncogene Oct 24;21(49): Cottone E., Orso F., Biglia N, Sismondi P & De Bortoli M. Role of coactivators and corepressors in seroid and nuclear receptor signaling: potential markers of tumor growth and drug sensitivity. Int. J. Biol. Markers (2001), 16 (3): Oberto M, Soncin I, Bovolin P, Voyron S, De Bortoli M, Dati C., Fasolo A, Perroteau I ERBB4 and neuregulin expression in the adult mouse olfactory bulb after peripheral denervation Eur. J. Neuroscience (2001): 14(3): Perissi V, Menini N, Cottone E., Capello D, Sacco M, Montaldo F and De Bortoli M. "AP 2 transcription factors in the regulation of ERBB2 gene transcription by oestrogen". (2000). Oncogene, 19: De Benedetti VM, Biglia N, Sismondi P & De Bortoli M. DNA chips: the future of Biomarkers Int. J. Biol. Markers (2000), 15: 1 9 (review) 29. Perroteau I, Oberto M, Soncin I, Voyron S, De Bortoli M, Bovolin P and Fasolo A. "Transregulation of ERBB expression in the mouse olfactory bulb". Cell. Mol. Biol. (1999) 45:

8 30. Maggiora P., Marchio' S., Stella M.C., Giai M., Belfiore A., De Bortoli M., Di Renzo M.F., Costantino A., Sismondi P. & Comoglio P.M. Overexpression of the RON gene in human breast carcinoma. Oncogene (1998), 16: De Bortoli M. and Dati C. Hormonal regulation of type I receptor tyrosine kinases in the mammary gland J. Mammary Gland Biol. Neopl. (1997), 2: Dati C., Maggiora P., Puech C., De Bortoli M., Escot C. " Expression of the erbb 2 proto oncogene during differentiation of the mammary gland in the rat." Cell Tissue Res. (1996), 285: Maggiora, P. & De Bortoli M. NDF/Heregulins stimulate expression of the erbb 2 tyrosine kinase growth factor receptor in human breast cancer. Ann. N. Y. Acad. Sci. (1996), 784: De Bortoli, M., Maggiora P., Capello D., Antoniotti S., Saviozzi S., Sapei M.L. and Dati C. Hormonal control of growth factor receptor expression Ann. N. Y. Acad. Sci. (1996), 784: Giai M, Roagna R, Ponzone R, De Bortoli M, Dati C & Sismondi P. "Prognostic and predictive relevance of c erbb 2 and ras expression in node positive and negative breast cancer". Anticancer Res. (1994), 14: Antoniotti S, Taverna D, Maggiora P, Sapei ML, Hynes NE, De Bortoli M. Oestrogen and EGF down regulate erbb2 oncogene protein expression in breast cancer cells by different mechanisms. Br. J. Cancer (1994), 70: Taverna D., Antoniotti S., Maggiora P., Dati C., De Bortoli M., and Hynes N.E. "ERBB2 expression in estrogen receptor positive breast tumor cells is regulated by growth modulatory reagents". Int. J. Cancer (1994), 56: De Bortoli M., Dati C., Antoniotti S., Maggiora P. and Sapei ML. "Hormonal regulation of c erbb 2 oncogene expression in breast cancer cells". J. Steroid Biochem. Molec. Biol. (1992), 43:

9 39. Antoniotti, S., Maggiora P., Dati, C. and De Bortoli M. "Tamoxifen up regulates c erbb 2 expression in estrogen responsive breast cancer cells "in vitro"". Eur. J. Cancer (1992), 28: Dati, C., Muraca, R., Tazartes, O., Antoniotti, S., Perroteau, I., Giai, M., Cortese, P., Sismondi, P., Saglio, G. and De Bortoli, M. "c erbb2 and ras expression levels in breast cancer are correlated and show a cooperative association with unfavorable clinical outcome." Int. J. Cancer (1991), 47: Piffanelli A., Giovannini G., Pelizzola D., De Bortoli M., Catozzi L., and Giganti M. "Steroid receptor assays: an italian quality assessment program" Ann. Ist. Super. Sanità (1991), 27: Dati C, Antoniotti S, Taverna D, Perroteau I, De Bortoli M "Inhibition of c erbb2 oncogene expression by estrogens in human breast cancer cells". Oncogene (1990), 5: Ardito G., Bigatti P., Lamberti L., Crovella S., De Bortoli M. "Uso delle tecniche degli enzimi di restrizione e del DNA ricombinante nello studio della variabilita' genetica in un gruppo di Primati non umani (Macaca fascicularis)". Antropologia contemporanea (1989), 12: Perroteau, I., Fracchia, S., Ferrara, B., De Bortoli M, Barone, D. "Safety tests for continuous cell lines used in biotechnology" in "Trends in drug development", RBMeetings 4. Editori A. Assandri, S. Fumero, RBM Publishing, Ivrea (Italy)(1989), pagg De Bortoli M, Dati C, Perroteau I, Panico S, Biffo S, Giai M, Catozzi L, Selvatici R, Piffanelli A, Sismondi P. "ras proto oncogene expression in human and experimental mammary tumors". in "Progress in Cancer Research and Therapy", Vol. 35: "Hormones and Cancer 3". Edited by F. Bresciani, RJB King, ME Lippman and JP Reynaud, Raven Press Ltd. New York, (1988), pagg De Bortoli M, Giai M, Piffanelli A, Sismondi P. "p21 ras expression in human breast cancer" in "Biology and Biochemistry of Normal and Cancer Cell Growth", Ed. by L. Castagnetta and I. Nenci,, Harwood Academic Publishers, Chur, London, U.K. (1988), pagg

10 47. Piffanelli, A., Pelizzola, D., De Bortoli, M., Giovannini, G., Messeri, G., Quercioli, M. e Fumero, S. "Dosaggio radiometrico dei recettori steroidei nel cancro mammario: Revisione del metodo con carbone destrano". Biochimica Clinica (1987), 11: A. Piffanelli, D. Pelizzola, G. Giovannini, M. De Bortoli, C. Dati, M. Giganti, L. Catozzi, L. Faggioli "Controllo di qualita' del dosaggio dei recettori dell'estradiolo e del progesterone in Italia nel 1986: revisione degli indici di affidabilita'". The Ligand Quarterly Ed. Ital. (1987), 6: Piffanelli A., Pelizzola D., De Bortoli M., Giovannini G. and Fumero S. "Determinazione dei recettori dell'estradiolo e del progesterone nel carcinoma mammario: programmi di controllo di qualita' in Italia". The Ligand Quarterly Ed. Italiana (1986), 5: Piffanelli A., Giovannini G., Pelizzola D., De Bortoli M. "Estrogen and progesterone measurement and its quality control in breast cancer: a reappraisal". Int. J. Biol. Markers (1986), 1: Piffanelli A., Giovannini G., Pelizzola D., Selvatici R., Catozzi L., Balestrieri L., DeBortoli M., Giai M., Bassi N., Sismondi P. "Simultaneous determination of H 222 (E.I.A.), ER D.C.C. and ER D5 (I.R.M.A.)." in "Endocrinology and Malignancy", Ed by E.E.Baulieu, S.Iacobelli and W.L.McGuire, The Parthenon Publishing Group, Carnforth, U.K. (1986), pagg De Bortoli M., Theillet C., Escot C., Perroteau I., Merlo G., Lidereau R., Callahan R. "ras proto oncogenes in mammary cancer". in "Endocrinology and Malignancy", Ed. by E.E.Baulieu, S.Iacobelli and W.L.McGuire, The Parthenon Publishing Group, Carnforth, U.K. (1986), pagg A. Piffanelli, Giovannini G., Pelizzola D., De Bortoli M., Perroteau I., Selvatici R., Catozzi L. and Balestreri L. "Estrogen and progesterone receptors as marker of hormono sensitivity in breast cancer: simultaneous determination of H 222, ER and PgR DCC, and ER D5". in "Receptors in Pharmacology", Editori A. Assandri, S. Fumero, RBM Publishing, Ivrea (1986), pagg

11 54. Gaudino G., De Bortoli M. and Lazarus L.H. "A bombesin related peptide in experimental mammary tumors in rats". Ann. N.Y. Acad. Sci. (1986), 464: Perroteau I, Salomon D, De Bortoli M, Kidwell W, Hazarika P, Pardue R, Dedman J,Tam J "Immunological detection and quantitation of alpha transforming growth factors in human breast carcinoma cells". Breast Cancer Res. Treat. (1986), 7: Piffanelli A., De Bortoli M., Fumero S., Pelizzola D., Agrimonti F., Frairia R. and Giovannini G. "Five years of quality control for steroid receptor assay in Italy". J. Nucl. Med. All. Sci. (1985), 29: Agrimonti F., Berruto G.P., Fornaro D., De Bortoli M., Fumero S., Frairia R., Pelizzola D., Giovannini G. and Piffanelli A. "Quality control for estrogen and progesterone receptor assay in human breast cancer: the influence of computation methods on intra and interlaboratory variability". Tumori (1985), 71: Piffanelli A., Pelizzola D., De Bortoli M., Agrimonti F., Frairia R., Giovannini G. and Fumero S. "Quality assurance for steroid receptor assay in human breast cancer: six years experience of the Italian Committee". Tumori (1985), 71: Tagliaferri P.S., Clair T., De Bortoli M. and Cho Chung Y.S. "Two classes of camp analogs synergistically inhibit p21 ras protein synthesis and phenotypic transformation of NIH/3T3 cells transfected with Ha MuSV DNA". Biochem. Biophys. Res. Commun. (1985), 130: De Bortoli M., Abou Issa H., Haley B.E. and Cho Chung Y. S. "Amplified expression of p21 ras protein in hormonedependent mammary carcinomas of humans and rodents". Biochem. Biophys. Res. Commun. (1985), 127: Giunta C., De Bortoli M., Sanchini M. and Stacchini A. "Activatory effect of two cardioglycosides on Cavia cobaia kidney Na,K ATPase activity". Gen. Pharmacol. (1985), 16: De Bortoli M. and Roggero P. "Electrophoretic desorption of intact virus from immunoadsorbent" Microbiologica (1985), 8:

12 63. Giunta C., De Bortoli M., Stacchini A. and Sanchini M. "Na,K ATPase from Xenopus laevis (Daudin) kidney and epidermis: high sensitivity towards regulatory compounds". Comp. Biochem. Physiol. (B) (1984), 79: De Bortoli M., Giunta C., Dati C. and Usseglio L. "Solubilization and purification of Na,K ATPase from the outer medulla of rabbit kidney". Boll. Soc. It. Biol. Sper. (1984), LX: De Bortoli M., Fumero S. and Mondino A. "Cyclic adenosine 3':5' monophosphate binding proteins in human mammary tumor cytosol and their relation to estrogen and progesterone receptors. A preliminary study". Boll. Soc. It. Biol. Sper. (1983), LIX: Piffanelli A., Fumero S., Pelizzola D., De Bortoli M., Giovannini G., Ricci L., Scaglianti G. and Mazzilli M. "Quality control of estradiol receptor assay in oncology". in "Nuclear Medicine and Biology", Vol. I, Ed. C. Reynaud, Pergamon Press, Paris (1982), pagg Piffanelli A., Fumero S., Pelizzola D., De Bortoli M., Giovannini G. and Tosi S.P. "Quality control of estradiol receptor assay: the Italian experience". in: "Radioimmunoassay and related procedures in medicine 1982", Ed. by the International Atomic Energy Agency, Vienna (1982), pagg De Bortoli M., Giunta C., Stacchini A. and Sanchini M. "Na,K ATPase from Xenopus laevis kidney and epidermis: ouabain interaction studies". Boll. Soc. It. Biol. Sper. (1982), LVIII: Giunta C., De Bortoli M., Sanchini M. and Stacchini A. "Sodium and potassium dependent adenosinetriphosphatase from Cavia cobaia kidney: interaction with very low cardiotonic steroid concentrations". Boll. Soc. It. Biol. Sper. (1982), LVIII: Giunta C., De Bortoli M., Treves S. and Vercelli R. "Na,K ATPase from Xenopus laevis (Daudin) kidney. Purification and characterization". Comp. Biochem. Physiol. (B) (1981), 68: De Bortoli M. and Giunta C. "Characterization of Na,K ATPase from Xenopus laevis kidney. Preliminary results". Boll. Soc. It. Biol. Sper. (1980), LVI:

13 72. Giunta C., De Bortoli M. and Brigidi R. "Na,K dependent adenosinetriphosphatase in rabbit kidney. Separation by affinity chromatography" Boll. Soc. It. Biol. Sper. (1979), LV: Giunta C. and De Bortoli M. "Na,K dependent adenosinetriphosphatase activity in mammalian kidney". Boll. Soc. It. Biol. Sper. (1979), LV: Patents 1. PANETTO A., REINERI S., CUTRUPI S., DE BORTOLI M. (2008). USO DI UN PEPTIDE DERIVATO DA ER ALFA PER IL RIPRISTINO DELLA SENSIBILITA' A COMPOSTI ANTIESTROGENICI IN CELLULE DI TUMORE MAMMARIO. TO2008A del 24/12/2008. Bioindustry Park del Canavese SPA. 2. CUTRUPI SANTINA, PANETTO ARIANNA, REINERI STEFANIA, DE BORTOLI M. (2010). USE OF A PEPTIDE DERIVED FROM ER ALPHA FOR RESTORING SENSITIVITY TO ANTIESTROGENIC COMPOUNDS IN BREAST TUMOUR CELLS. WO2010/072843A3. Bioindustry Park Silvano Fumero SpA. Congresses, Conferences The most important invited talks. Estrogen: genomic and nongenomic effects. 7th European Congress on Menopause, Istanbul, 3 7 June The intrinsic complexity of the target: the paradigm of estrogenic regulation. 38 Congresso SIBIOC, Torino, settembre La risposta genomica agli estrogeni ed antiestrogeni, Simposio Carcinoma mammario: nuovi suggerimenti dalla ricerca di base, CERMS, Torino, 19 maggio 2006 La risposta genomica agli ormoni estrogeni in Simposio inaugurale del Centro SysBioM I Sistemi Complessi in Biologia e Medicina Molecolare, Torino 20 gennaio Molecular Characterization of Breast Cancer Aggressiveness. 5th International Symposium on Women s Health and Menopause, Firenze, Aprile ERBB2. Corso di aggiornamento in evidence based medicine "Dal laboratorio alla clinica: biomarcatori in "evidenza". Applicazioni in Oncologia" Laguna Palace Hotel, Venezia Mestre, novembre 2004.

14 Risposte geniche agli estrogeni nel carcinoma mammario ormonoresponsivo: vie di regolazione secondarie. Seminario presso la Seconda Università degli Studi di Napoli, Complesso di Sant Andrea delle Dame, 22/07/2004. Gene expression profiling in breast cancer for prediction of prognosis and response: advantages overcome problems. Italian Japanes Joint Seminar: Toward the Post sequencing Era: New opportunities for Scientific Cooperation between Italy and Japan in basic and applied Cancer Research. Tokyo, November 4, Molecular characterization of breast cancer aggressiveness Convegno Marcatori Molecolari Emergenti in Oncologia Terapia mirata, Indicatori di risposta, Chemioprevenzione, Rovigo, IRCC, 20 settembre Nuove Tecnologie: Promesse e Cautele. 6 Simposio Ligand Assay 2000, Bologna ottobre Caratterizzazione del profilo di espressione genica nei tumori come nuovo approccio diagnostico». Advanced Technology for the Clinical Laboratory and Biotechnology: ATB Corsi Milano, 9 10 Novembre Quality Control in Molecular Pathology in 7th EORTC Breast Cancer Working Conferenca, Bordeaux, France, Sept.10 13, Cross talk tra erbb2 e recettori steroidei nel carcinoma mammario in Ruolo dell oncoproteina erbb2 nella trasformazione neoplastica e nella diagnosi, prognosi e terapia dei tumori umani, Organizzato da Istituto Nazionale per lo Studio e la Cura dei Tumori, Milano, 19 gennaio Hormonal control of growth factor receptor expression in Propedeutics to Cancer Management 39th Course Biology and Biochemistry of Normal and Cancer Cell Growth, E. Majorana Centre for Scientific Culture, Erice, 1 6 Aprile Modulazione ormonale della espressione degli oncogeni e dei geni repressori in Endocrinologia ed endocrinoterapia dei tumori. Organizzato da Scuola Internazionale di Oncologia e Medicina Sperimentale. Santa Margherita Ligure, dicembre Meccanismi d azione del tamoxifene non mediati dal recettore per gli estrogeni in Nuove acquisizioni farmacologiche e nuove indicazioni cliniche degli antiestrogeni, organizzato da U.F.G.O., Roma, Ottobre Analisi di oncogeni ed antioncogeni Laboratorio di Oncologia: dalla ricerca di base all utilizzo clinico. Organizzato da Scuola Internazionale di Oncologia e Medicina Sperimentale. Roma, dicembre "Analysis of Oncogenes in Human Tumors" n "From basic research in oncology to clinical application", The XIX Meeting of the International Society of Oncodevelopmental Biology and Medicine, Siena, October 13 17, Gli oncogeni nella caratterizzazione delle neoplasie umane in 22 Congresso Nazionale della Società Italiana di Biochimica Clinica, Bologna, ottobre 1990.

15 Proposta di standardizzazione europea dell analisi dell oncogene erbb2/neu in XIII Corso di aggiornamento in Oncologia Medica, Organizzato dalla Ass. It. Oncologia Medica, Rimini, 3 7 giugno Oncogeni: metodiche di analisi in Cinetica cellulare, 4 Corso teorico pratico, Organizzato da SIBIOC, SICCAB, AIRB, INRCA, Firenze, 31 maggio 2 giugno Significato prognostico degli oncogeni c erbb2 e ras nel carcinoma primario della mammella in Il carcinoma mammario: attualità in diagnostica e terapia, Organizzato da Anatomia Patologica e Ricerche Cliniche, USL 10, Jesi, 1 dicembre Regulation de l expression de c erbb2 neu dans le cellules de cancer mammaire. Implication sur la valeur prognostique dans le cancer du sein. organizzato da INSERM Unité 148 Hormones et Cancer, Montpellier, 20 Novembre La biochimica dei recettori in Recettori ormonali e carcinoma mammario: bilancio di un decennio. Organizzato da Società Italiana di Biochimica Clinica, Firenze, 17 novembre "Significance of H ras oncogene and Alpha Transforming Growth Factor in breast cancer" International Course "Advances in Diagnostic Laboratory Techniques for Breast Cancer", Boston (USA), 6 7 November, 1986.

16 Chapters in books De Bortoli M. DNA Dizionario di Biologia, Ed. by A. Fasolo, Edizioni UTET Torino, De Bortoli M. RNA Dizionario di Biologia, Ed. by A. Fasolo, Edizioni UTET Torino, De Bortoli, M. & Marchiò, S. "Antiestrogeni ed oncogeni nel cancro mammario" in "Farmacologia della nuova generazione di antiestrogeni". Editori G. Scambia, P. Benedetti Panici, G. Isola, S. Mancuso. Soc. Editrice Universo, Roma, 1996, pagg De Bortoli M. "L'oncogene erbb2 nel cancro mammario umano: significato prognostico e predittivo, e aspetti regolativi" in "La cellula neoplastica: biologia, diagnosi e terapia molecolare", Editori A. Nicolin, P. Comoglio, Edizioni UTET Torino 1996, pagg De Bortoli, M. Meccanismi d azione del Tamoxifene non mediati dal recettore per gli estrogeni. in Nuove acquisizioni farmacologiche e nuove indicazioni cliniche degli antiestrogeni, Ed. by G. Scambia, G. Isola, P. Benedetti Panici, S. Mancuso, pagg. 1 16, Soc. Editrice Universo, Roma, 1995.